Rancho Santa Fe Batu Biologics Celebration

3 February 2015

Batu Biologics’ recent celebration featured Nobel Prize winner Dr. Kary Mullis and Lasker Award winner Dr. Napoleone Ferrara. The party coincided with Batu’s investigational drug application submission for its lung cancer anti-angiogenic immunotherapy ValloVax™. Download the event photos and captions from the Rancho Santa Fe Review....

Read Full Article About Businesswire.com

Batu Biologics Appoints Alan Lewis to Chairman of the Board

13 January 2015

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board World Class Industry Expert to Accelerate Development of Cancer Immunotherapeutic Platform after IND Filing for Lung Cancer Indication Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. … Continue reading "Batu Biologics Appoints Alan Lewis to Chairman of the Board"....

Read Full Article About Businesswire.com

Startup applies to test cancer therapy

5 January 2015

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors. The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung … Continue reading "Startup applies to test cancer therapy"....

Read Full Article About Businesswire.com

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery? These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of … Continue reading "Bringing Innovative Weapons To the Cancer Battlefront"....

Read Full Article About Businesswire.com

Startup Conducts Unusual Funding ‘Experiment’

A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine. “If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion … Continue reading "Startup Conducts Unusual Funding ‘Experiment’"....

Read Full Article About Businesswire.com

Batu Biologics Releases 2014 Shareholder Letter

2 January 2015

Batu Biologics is pleased to announce the release of the 2014 Shareholder Letter discussing the year-end progress in the development of its anti-angiogenic lung cancer vaccine, ValloVax. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Biologics Files IND Application for ValloVax

11 December 2014

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy with FDA Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead … Continue reading "Batu Biologics Files IND Application for ValloVax"....

Read Full Article About Businesswire.com

Batu Biologics appoints Chief Financial Officer

5 December 2014

Batu Biologics Appoints Gerry Berg as Chief Financial Officer Seasoned executive to leverage experience in promising new immunotherapy venture Batu Biologics, a San Diego based immunotherapy company working to develop therapeutics targeting the tumor vasculature, announced today the appointment of Gerry Berg as Chief Financial Officer. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Immunologist Joins Scientific Advisory Board

19 November 2014

Batu Biologics Recruits Cancer Immunologist to Scientific Advisory Board Collaboration of IND-enabling experiments for ValloVax™ with Dr. Fang Batu Biologics, an immunotherapy company working to develop ValloVax, an anti-angiogenic cancer vaccine, announced today the addition of Dr. Deyu Fang to its Scientific Advisory Board. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Inventor of UCSD Licensed Technology Joins SAB

12 November 2014

Batu Biologics Recruits Inventor of Licensed UCSD Cancer Immunotherapy to Scientific Advisory Board Dr. Messmer to Assist in the Clinical Development of the ValloVax™ Lung Cancer Vaccine Batu Biologics, an immunotherapy company developing the ValloVax™ anti-angiogenic lung cancer vaccine, announced today the addition Dr. Davorka Messmer to its Scientific Advisory Board (SAB). Read the full … Continue reading "Inventor of UCSD Licensed Technology Joins SAB"....

Read Full Article About Businesswire.com
1 2 3 4 5 6